Pharmacy Grand Rounds
How Low Should LDL-C Go? The Role of Non-Statin Therapy in the Management of Blood Cholesterol 

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Cardiovascular disease is the most common cause of death in the United States and worldwide. A primary risk factor for developing cardiovascular disease is elevated blood cholesterol levels. Treatment of dyslipidemia is essential for prevention of atherosclerotic cardiovascular events, including stroke and myocardial infarction. Although dyslipidemia is most commonly managed by statin therapy, there are several non-statin medications that should be considered as adjunct therapy when further reduction in LDL-C is necessary. This presentation will describe the role of non-statin therapy in the management of blood cholesterol for prevention of major cardiovascular events.

At the conclusion of this knowledge-based CE session, participants should be able to:

• Review guideline recommendations for management of blood cholesterol
• Describe the risks and benefits associated with adjunct non-statin therapy
• Identify patient-specific characteristics in which PCSK9 inhibitor therapy should be considered

Session Announcement

Session Slides

FACULTY INFORMATION

Hannah L. Poppen, PharmD
PGY2 Ambulatory Care Pharmacy Resident
Mayo Clinic Health System - Mankato

Hannah received a Doctor of Pharmacy degree from South Dakota State University in Brookings, SD followed by subsequent PGY1 training at the Sioux Falls Veterans Affairs Health Care System.  Dr. Poppen is a current PGY2 Ambulatory Care Pharmacy Resident at Mayo Clinic Health System – Mankato with practice interest in cardiology, endocrinology, and geriatrics.

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Hannah L. Poppen, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will not be discussed during this presentation.

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS